On July 31, Dentsu Inc. acquired 100% of the shares in Synergy Medical Communications (Synergy MC), a specialized medical agency focused on marketing communications for prescription drugs, from its parent company, Apoplus Station*.
Amidst recent national healthcare system reforms driven by a declining birthrate and aging population, along with shifts in drug discovery trends, the marketing of prescription drugs—particularly for pharmaceutical companies—is facing a major turning point.
Amidst this, client companies increasingly expect solutions from our group, such as insights into healthcare professionals, patients, and society; marketing methods that maximize customer value; and support for developing new services in healthcare. Establishing a structure capable of comprehensively meeting these needs has become an urgent priority.
Furthermore, while the Dentsu Group currently provides specialized medical services in Japan through Dentsu Sadler & Hennessy, it faced capacity constraints in accepting orders for prescription drugs because a single company cannot handle multiple products targeting the same disease.
This acquisition addresses these challenges. Synergy MC joining the Dentsu Group establishes a second line of service, enhancing the organization's capabilities in the medical field.
Going forward, Dentsu Group will pursue further service innovation by combining its unique BtoC expertise and know-how with Synergy MC's high level of medical specialization.
[SynergyMC Overview]
Company Name: Synergy Medical Communications Inc.
URL:http://sygmc.co.jp/
Location: Front Place Nihonbashi, 2-14-1 Nihonbashi, Chuo-ku, Tokyo (Scheduled to relocate within the year)
Phone: 03-4533-1100 (Main)
Representative: President and CEO, Kyuichi Kobayashi (currently Head of Dentsu Business Creation Center)
Established: March 2011 (Predecessor company established September 1992)
Shareholder Structure: Dentsu Inc. 100%
Capital: 100 million yen
Sales: Fiscal Year 2014 (Ending March 2015) ¥817 million
*Excludes sales from the publishing division, which was spun off into a separate company in May 2015
Number of Employees: 23
Business Activities: Formulation and implementation of marketing and communication strategies for prescription drugs; planning and production of patient-facing communications; planning and production of various tools and materials; planning and operation of events, seminars, symposiums, and study groups, etc.
*About Apoplus Station Co., Ltd.
Primarily engaged in CSO (outsourcing services for marketing and sales activities related to pharmaceuticals, etc.) and human resources services.
Dentsu Inc. News Release http://www.dentsu.co.jp/news/release/2015/0731-004108.html
